<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02368457</url>
  </required_header>
  <id_info>
    <org_study_id>ORN-2014-16</org_study_id>
    <nct_id>NCT02368457</nct_id>
  </id_info>
  <brief_title>Management of Mandibular ORN: PENTO as Medical Treatment</brief_title>
  <acronym>PENTO</acronym>
  <official_title>Advances in the Management of Mandibular Osteoradionecrosis: Pentoxifylline and Tocopherol as Medical Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Vall d'Hebron</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mandibular osteoradionecrosis, despite its low incidence, remains being the most problematic
      and irreversible complication after head and neck radiotherapy with no medical treatment to
      limit or reduce symptoms.

      Different clinical trials have shown a significant scientific evidence that the treatment
      with pentoxifylline + tocopherol achieves a certain effectiveness in the treatment of the
      tissue fibrosis. This study proposes to use this drugs to determine if there is healing of
      mandibular osteoradionecrosis and/or a symptomatic improvement as well.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mandibular osteoradionecrosis which occurs after the use of radiation therapy for the
      treatment of head and neck cancer remains being the most problematic and irreversible
      complication despite its low incidence with no medical treatment to limit or reduce symptoms.

      Clinical trials conducted to date have shown a significant scientific evidence that the
      treatment with pentoxifylline + tocopherol achieves a certain effectiveness in the treatment
      of the tissue fibrosis that have been irradiated based on the properties of this drugs in
      increased tissue oxygenation and their antioxidant effect.

      The aim of this study is to determine if there is a clinical improvement of mandibular
      osteoradionecrosis using Pentoxifylline in combination with Tocopherol as treatment because,
      currently, there is no effective treatment to achieve bone healing and/or a symptomatic
      improvement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">January 1, 2018</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone and/or Tissue Healing as Measured With the Classification of ORN Stages, Area of Bone Exposed (mm2) and Radiological Findings (OPG).</measure>
    <time_frame>From baseline to 1, 3, 6, and 9 months of starting treatment</time_frame>
    <description>Clinical healing assessment as measured with the classification of ORN stages, area of bone exposed (mm2) and radiological findings (OPG).
Intraoral bone exposure is measured in mm2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Symptoms Evaluation, Measured Using the LENT-SOMA Scale</measure>
    <time_frame>From baseline to 1,3, 6, 9 months of starting treatment</time_frame>
    <description>Evaluation of symptoms improvement using the LENT-SOMA scale (Late Effect Normal Tissue Task Force / Subjective, Objective, Management, Analytic scale).
To examine the LENT/SOMA scale prospectively using interviews and questionnaires
Assessments were made from baseline to 1, 3, 6 and 9 months of starting treatments. The acceptability and feasibility of using the scales was examined using compliance in completion of the questionnaires.
Maximum score: 36 Minimum score: 0
Questionnaires have been completed for 24 patients after treatment. Higher values represents worse outcome.
Scale categories:
Subjective: pain, nutritional problems, difficulty in mouth openning. Objective: bone exposure, trismus, Management: analgesic treatment, oral treatment, nutrition. Analytic: radiological findings.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Osteoradionecrosis</condition>
  <arm_group>
    <arm_group_label>Pentoxifylline and Tocopherol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: pentoxifylline with tocopherol Combination of pentoxifylline and tocopherol during a minimum of 6 months and a maximum of 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No drug treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline and Tocopherol</intervention_name>
    <description>pentoxifylline with tocopherol Pentoxifylline 800 mg/day, oral (1cp 400 mg twice a day) + Vitamin E (alfa-tocopherol) 1000 UI/day, oral (1cp 400UI twice a day + 1cp200UI once a day) during 24 months (maximum).</description>
    <arm_group_label>Pentoxifylline and Tocopherol</arm_group_label>
    <other_name>PENTO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 18 years and under 90 years old.

          -  Patients who have received radiotherapy after being diagnosed with head and neck
             cancer and currently are diagnosticated of mandibular osteoradionecrosis (any clinical
             stage)

          -  Follow-up for at least a year after the radiation treatment is completed.

          -  Absence of tumor at the time of recruitment.

          -  Patients with the capacity to give informed consent

        Exclusion Criteria:

          -  Allergy or hypersensitivity to Pentoxifylline or others xanthines, or to Tocopherol
             (vitamin E).

          -  Patients taking oral anticoagulants (acenocoumarol, warfarin).

          -  Known hemorrhagic/coagulation disorder.

          -  Vitamin K deficiency due to any cause.

          -  Use of estrogens oral contraceptives.

          -  Serious bleeding or extensive retinal hemorrhage.

          -  Ischaemic heart diseases, including recent Myocardial Infarction.

          -  Serious cardiac arrhythmia.

          -  Severe LIVER DISEASE.

          -  Severe renal failure (creatinine clearance &lt;30 mL/min).

          -  Hypotension.

          -  Female patients who are pregnant or lactating

          -  Any other situation or condition that, in the opinion of the INVESTIGATOR, may
             interfere with optimal PARTICIPATION in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miriam Martos-Fernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oral and Maxillofacial Surgery (Vall d'Hebrón Hospital)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vall d'Hebrón Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Robard L, Louis MY, Blanchard D, Babin E, Delanian S. Medical treatment of osteoradionecrosis of the mandible by PENTOCLO: preliminary results. Eur Ann Otorhinolaryngol Head Neck Dis. 2014 Dec;131(6):333-338. doi: 10.1016/j.anorl.2013.11.006. Epub 2014 Jun 30.</citation>
    <PMID>24993781</PMID>
  </reference>
  <reference>
    <citation>Delanian S, Chatel C, Porcher R, Depondt J, Lefaix JL. Complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO): a phase II trial. Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):832-9. doi: 10.1016/j.ijrobp.2010.03.029. Epub 2010 Jul 16.</citation>
    <PMID>20638190</PMID>
  </reference>
  <reference>
    <citation>Delanian S, Depondt J, Lefaix JL. Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial. Head Neck. 2005 Feb;27(2):114-23.</citation>
    <PMID>15641107</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2015</study_first_posted>
  <results_first_submitted>February 18, 2016</results_first_submitted>
  <results_first_submitted_qc>October 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 20, 2016</results_first_posted>
  <last_update_submitted>February 24, 2018</last_update_submitted>
  <last_update_submitted_qc>February 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Vall d'Hebron</investigator_affiliation>
    <investigator_full_name>Miriam Martos-Fernandez</investigator_full_name>
    <investigator_title>Oral and Maxillofacial Surgeon</investigator_title>
  </responsible_party>
  <keyword>Mandibular osteoradionecrosis</keyword>
  <keyword>Tocopherol</keyword>
  <keyword>pentoxifylline</keyword>
  <keyword>vitamine E</keyword>
  <keyword>wounds and injuries</keyword>
  <keyword>antioxidants</keyword>
  <keyword>free radical scavengers</keyword>
  <keyword>radiation-protective agents</keyword>
  <keyword>vasodilatadors agents</keyword>
  <keyword>osteonecrosis</keyword>
  <keyword>mandible</keyword>
  <keyword>extraoral fistula</keyword>
  <keyword>exposed bone</keyword>
  <keyword>necrotic bone</keyword>
  <keyword>head and neck radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoradionecrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pentoxifylline and Tocopherol</title>
          <description>Drug: pentoxifylline with tocopherol Combination of pentoxifylline and tocopherol during a minimum of 6 months and a maximum of 24 months.
Pentoxifylline and Tocopherol: pentoxifylline with tocopherol Pentoxifylline 800 mg/day, oral (1cp 400 mg twice a day) + Vitamin E (alfa-tocopherol) 1000 UI/day, oral (1cp 400UI twice a day + 1cp200UI once a day) during 24 months (maximum).</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>No drug treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pentoxifylline and Tocopherol</title>
          <description>Drug: pentoxifylline with tocopherol Combination of pentoxifylline and tocopherol during a minimum of 6 months and a maximum of 24 months.
Pentoxifylline and Tocopherol: pentoxifylline with tocopherol Pentoxifylline 800 mg/day, oral (1cp 400 mg twice a day) + Vitamin E (alfa-tocopherol) 1000 UI/day, oral (1cp 400UI twice a day + 1cp200UI once a day) during 24 months (maximum).</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>No drug treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="10"/>
                    <measurement group_id="B2" value="55" spread="10"/>
                    <measurement group_id="B3" value="56" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Exposed bone</title>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" spread="10"/>
                    <measurement group_id="B2" value="15" spread="10"/>
                    <measurement group_id="B3" value="12.5" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone and/or Tissue Healing as Measured With the Classification of ORN Stages, Area of Bone Exposed (mm2) and Radiological Findings (OPG).</title>
        <description>Clinical healing assessment as measured with the classification of ORN stages, area of bone exposed (mm2) and radiological findings (OPG).
Intraoral bone exposure is measured in mm2.</description>
        <time_frame>From baseline to 1, 3, 6, and 9 months of starting treatment</time_frame>
        <population>mean of intraoral bone exposure (measured in mm2) from baseline to 1, 3, 6, 9, 12 and 18 months of starting treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline and Tocopherol</title>
            <description>Drug: pentoxifylline with tocopherol Combination of pentoxifylline and tocopherol during a minimum of 6 months and a maximum of 24 months.
Pentoxifylline and Tocopherol: pentoxifylline with tocopherol Pentoxifylline 800 mg/day, oral (1cp 400 mg twice a day) + Vitamin E (alfa-tocopherol) 1000 UI/day, oral (1cp 400UI twice a day + 1cp200UI once a day) during 24 months (maximum).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Standard treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Bone and/or Tissue Healing as Measured With the Classification of ORN Stages, Area of Bone Exposed (mm2) and Radiological Findings (OPG).</title>
          <description>Clinical healing assessment as measured with the classification of ORN stages, area of bone exposed (mm2) and radiological findings (OPG).
Intraoral bone exposure is measured in mm2.</description>
          <population>mean of intraoral bone exposure (measured in mm2) from baseline to 1, 3, 6, 9, 12 and 18 months of starting treatment</population>
          <units>mm2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 month of starting treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="10" upper_limit="18"/>
                    <measurement group_id="O2" value="15" lower_limit="10" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 month of starting treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="10" upper_limit="16"/>
                    <measurement group_id="O2" value="15" lower_limit="10" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 month of starting treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="10" upper_limit="13"/>
                    <measurement group_id="O2" value="15" lower_limit="10" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 month of starting treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="8" upper_limit="12"/>
                    <measurement group_id="O2" value="15" lower_limit="10" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Symptoms Evaluation, Measured Using the LENT-SOMA Scale</title>
        <description>Evaluation of symptoms improvement using the LENT-SOMA scale (Late Effect Normal Tissue Task Force / Subjective, Objective, Management, Analytic scale).
To examine the LENT/SOMA scale prospectively using interviews and questionnaires
Assessments were made from baseline to 1, 3, 6 and 9 months of starting treatments. The acceptability and feasibility of using the scales was examined using compliance in completion of the questionnaires.
Maximum score: 36 Minimum score: 0
Questionnaires have been completed for 24 patients after treatment. Higher values represents worse outcome.
Scale categories:
Subjective: pain, nutritional problems, difficulty in mouth openning. Objective: bone exposure, trismus, Management: analgesic treatment, oral treatment, nutrition. Analytic: radiological findings.</description>
        <time_frame>From baseline to 1,3, 6, 9 months of starting treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline and Tocopherol</title>
            <description>Drug: pentoxifylline with tocopherol Combination of pentoxifylline and tocopherol during a minimum of 6 months and a maximum of 24 months.
Pentoxifylline and Tocopherol: pentoxifylline with tocopherol Pentoxifylline 800 mg/day, oral (1cp 400 mg twice a day) + Vitamin E (alfa-tocopherol) 1000 UI/day, oral (1cp 400UI twice a day + 1cp200UI once a day) during 24 months (maximum).</description>
          </group>
          <group group_id="O2">
            <title>CONTROL</title>
            <description>No drug treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Symptoms Evaluation, Measured Using the LENT-SOMA Scale</title>
          <description>Evaluation of symptoms improvement using the LENT-SOMA scale (Late Effect Normal Tissue Task Force / Subjective, Objective, Management, Analytic scale).
To examine the LENT/SOMA scale prospectively using interviews and questionnaires
Assessments were made from baseline to 1, 3, 6 and 9 months of starting treatments. The acceptability and feasibility of using the scales was examined using compliance in completion of the questionnaires.
Maximum score: 36 Minimum score: 0
Questionnaires have been completed for 24 patients after treatment. Higher values represents worse outcome.
Scale categories:
Subjective: pain, nutritional problems, difficulty in mouth openning. Objective: bone exposure, trismus, Management: analgesic treatment, oral treatment, nutrition. Analytic: radiological findings.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 month of starting treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="13.2" upper_limit="15.8"/>
                    <measurement group_id="O2" value="15.5" lower_limit="14" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 month of starting treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="13" upper_limit="15"/>
                    <measurement group_id="O2" value="15.5" lower_limit="14" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 month of starting treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="13" upper_limit="15"/>
                    <measurement group_id="O2" value="15.5" lower_limit="14" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 month of starting treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="12" upper_limit="14.6"/>
                    <measurement group_id="O2" value="15.5" lower_limit="14" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pentoxifylline and Tocopherol</title>
          <description>Drug: pentoxifylline with tocopherol Combination of pentoxifylline and tocopherol during a minimum of 6 months and a maximum of 24 months.
Pentoxifylline and Tocopherol: pentoxifylline with tocopherol Pentoxifylline 800 mg/day, oral (1cp 400 mg twice a day) + Vitamin E (alfa-tocopherol) 1000 UI/day, oral (1cp 400UI twice a day + 1cp200UI once a day) during 24 months (maximum).</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Standard treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Miriam Martos</name_or_title>
      <organization>Oral and Maxillofacial Surgeon</organization>
      <phone>+34932746179</phone>
      <email>miryam.martos@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

